Cargando…
Profile of humoral and cellular immune responses to single doses of BNT162b2 or ChAdOx1 nCoV-19 vaccines in residents and staff within residential care homes (VIVALDI): an observational study
BACKGROUND: Residents of long-term care facilities (LTCFs) have been prioritised for COVID-19 vaccination because of the high COVID-19 mortality in this population. Several countries have implemented an extended interval of up to 12 weeks between the first and second vaccine doses to increase popula...
Autores principales: | Tut, Gokhan, Lancaster, Tara, Krutikov, Maria, Sylla, Panagiota, Bone, David, Kaur, Nayandeep, Spalkova, Eliska, Bentley, Christopher, Amin, Umayr, Jadir, Azar T, Hulme, Samuel, Butler, Megan S, Ayodele, Morenike, Bruton, Rachel, Shrotri, Madhumita, Azmi, Borscha, Fuller, Chris, Irwin-Singer, Aidan, Hayward, Andrew, Copas, Andrew, Shallcross, Laura, Moss, Paul |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8376213/ https://www.ncbi.nlm.nih.gov/pubmed/34430954 http://dx.doi.org/10.1016/S2666-7568(21)00168-9 |
Ejemplares similares
-
Severe Acute Respiratory Syndrome Coronavirus 2 Anti-Spike Antibody Levels Following Second Dose of ChAdOx1 nCov-19 or BNT162b2 Vaccine in Residents of Long-term Care Facilities in England (VIVALDI)
por: Stirrup, Oliver, et al.
Publicado: (2022) -
Antibody and cellular immune responses following dual COVID-19 vaccination within infection-naive residents of long-term care facilities: an observational cohort study
por: Tut, Gokhan, et al.
Publicado: (2022) -
Strong peak immunogenicity but rapid antibody waning following third vaccine dose in older residents of care homes
por: Tut, Gokhan, et al.
Publicado: (2023) -
Prevalence and duration of detectable SARS-CoV-2 nucleocapsid antibodies in staff and residents of long-term care facilities over the first year of the pandemic (VIVALDI study): prospective cohort study in England
por: Krutikov, Maria, et al.
Publicado: (2022) -
Vaccine effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against SARS-CoV-2 infection in residents of long-term care facilities in England (VIVALDI): a prospective cohort study
por: Shrotri, Madhumita, et al.
Publicado: (2021)